Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
596 hedge funds and large institutions have $23.4B invested in Alexion Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 81 funds opening new positions, 219 increasing their positions, 225 reducing their positions, and 64 closing their positions.
27% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 64
2% more funds holding
Funds holding: 587 → 596 (+9)
8% more call options, than puts
Call options by funds: $468M | Put options by funds: $434M
3% less repeat investments, than reductions
Existing positions increased: 219 | Existing positions reduced: 225
6% less funds holding in top 10
Funds holding in top 10: 17 → 16 (-1)
7% less capital invested
Capital invested by funds: $25.3B → $23.4B (-$1.85B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$295M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$193M |
| 3 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$144M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$117M |
| 5 |
Millennium Management
New York
|
+$107M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$207M |
| 2 |
Goldman Sachs
New York
|
-$201M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$154M |
| 4 |
Sands Capital Management
Arlington,
Virginia
|
-$133M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$115M |
ALXN Hedge Fund Activity: Q1 2018 in Review
596 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2018, worth a combined $23.4B — down 7.3% from $25.3B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new ALXN positions and 64 closed out — a net gain of 17 holders — while 219 added to existing stakes and 225 trimmed.
The largest buyer was Jennison Associates, adding an estimated $295M. The largest seller was State Street, cutting an estimated $207M.
- 596 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q1 2018, up from 587 in Q4 2017.
- Funds reported $23.4B of Alexion Pharmaceuticals stock for Q1 2018, down 7.3% quarter-over-quarter.
- 81 funds opened new Alexion Pharmaceuticals positions in Q1 2018 and 64 closed out, a net change of +17 holders.
- The largest Alexion Pharmaceuticals buyer in Q1 2018 was Jennison Associates, an estimated $295M added.
- The largest Alexion Pharmaceuticals seller in Q1 2018 was State Street, an estimated $207M sold.
Based on aggregated 13F filings for Q1 2018.